142335-42-0

Basic information

• Product Name: BOC-7-HYDROXY-TIC-OH
• Synonyms: BOC-[3S]-1,2,3,4-TETRAHYDROISOQUINOLINE-7-HYDROXY-3-CARBOXYLIC ACID;BOC-7-HYDROXY-(S)-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID;BOC-7-HYDROXY-TIC-OH;BOC-L-7-HYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID;BOC-HYDROXY-TIC-OH;BOC-L-TIC(7-OH)-OH;BOC-L-TIC(OH)-OH;BOC-TIC(7-HYDROXY)-OH
• CAS NO: 142335-42-0
• Molecular Formula: C₁₅H₁₉NO₅
• Molecular Weight: 293.32
• Mol File: 142335-42-0.mol

Chemical Properties

• Boiling Point: 496.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.302±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 2.91±0.20(Predicted)
• CAS DataBase Reference: BOC-7-HYDROXY-TIC-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-7-HYDROXY-TIC-OH(142335-42-0)
• EPA Substance Registry System: BOC-7-HYDROXY-TIC-OH(142335-42-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 142335-42-0(Hazardous Substances Data)

Usage

Uses

Used in Peptide Chemistry:
BOC-7-HYDROXY-TIC-OH is used as a protecting group for amino acids to facilitate the synthesis of peptides and proteins. It allows for the introduction of specific functionalities into peptide chains, enabling selective chemical reactions and control over the desired properties of the final peptide product.
Used in Biochemistry Research:
In the field of biochemistry, BOC-7-HYDROXY-TIC-OH is utilized for its ability to protect amino acids during peptide synthesis, providing researchers with greater control over the chemical reactions involved in creating complex peptide structures.
Used in Pharmaceutical Development:
BOC-7-HYDROXY-TIC-OH is employed in the development of pharmaceuticals, where its role in peptide synthesis is crucial for creating new drugs and therapeutic agents. Its ability to protect amino acids and control the properties of peptide products contributes to the advancement of drug discovery and design.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 142335-40-8 (S)-1,2,3,4-Tetrahydro-7-hydroxy-6,8-diiodoisoquinoline-3-carboxylic acid 
• 300-39-0 3,5-diiodo-l-tyrosine 
• 262616-16-0 methyl (S)-2-tert-butoxycarbonyl-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 128502-56-7 (3S)-1,2,3,4-tetrahydro-7-hydroxy-isoquinoline-3-carboxylic acid 
• 34619-03-9 tert-butyldicarbonate 
• 142335-41-9 (S)-2-(tert-butoxycarbonyl)-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 

Downstream Products

• 1287261-13-5 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-2-phenethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 1287261-11-3 (S)-7-(2-(hydroxyamino)-2-oxoethoxy)-N-(4-methoxyphenyl)-2-(3-phenylpropyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 
• 1223620-63-0 (S)-tert-butyl 7-(2-methoxy-2-oxoethoxy)-3-((4-methoxyphenyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-61-8 (S)-tert-butyl 7-(2-methoxy-2-oxoethoxy)-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-56-1 (S)-tert-butyl 7-(2-methoxy-2-oxoethoxy)-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-43-6 (S)-tert-butyl 3-(4-fluorophenylcarbamoyl)-7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-37-8 (S)-tert-butyl 3-(benzylcarbamoyl)-7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-41-4 (S)-tert-butyl 7-hydroxy-3-(o-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-49-2 (S)-tert-butyl 3-(2,4-dimethylphenylcarbamoyl)-7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-42-5 (S)-tert-butyl 7-hydroxy-3-(m-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-46-9 (S)-tert-butyl 3-(3-chlorophenylcarbamoyl)-7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-36-7 (S)-tert-butyl 7-hydroxy-3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-38-9 (S)-tert-butyl 7-hydroxy-3-(phenethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1223620-39-0 (S)-tert-butyl 7-hydroxy-3-((4-methoxyphenyl)carbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant articles and documents

Photophysics of 7-hydroxytetrahydroisoquinoline-3-carboxylic acid and its derivatives

The following derivatives of 7-hydroxytetrahydroisoquinoline-3-carboxylic acid {Tic(OH) [I]}, a conformationally restricted analogue of tyrosine, were synthesized for the purpose of photophysical studies and in order to elucidate the nature of tyrosine fluorescence and its decay: Ac-Tic(OH) [II], Ac-Tic(OH)-NHMe [III], Tic(OH)-NHMe [IV], Ala-Tic(OH) [V], Ac-Ala-Tic(OH) [VI], and Tic(OH)-Gly-NH2 [VII]. For the simple Tic(OH) derivatives I-IV, the N-methylamide was found to be a more effective quencher than the acetyl group. For the peptidic derivatives V-VII the highest quenching of the fluorescence of the phenolic chromophore was observed in the case of Ala-Tic(OH). The simple Tic(OH) derivatives I-IV were also the subject of theoretical studies (MOPAC 93). The obtained thermodynamic parameters (MOPAC calculations) and the fluorescence components were discussed on the basis of the rotamer theory in order to explain the participation of an individual rotamer in the complex process of the fluorescence decay of tyrosine.

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

PROTEOLYSIS-TARGETING CHIMERAS

The present disclosure provides compounds of the formula (I) wherein these compounds contain a ligand which binds to one or more target proteins such as CDK4 or CDK6 and a ligand which binds to the machinery associated with the ubiquitinating protein machinery. Also provided herein are methods of using these compounds in compositions or methods of treating patients with these compounds for the treatment of a disease or disorders such as cancer.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

SUBSTITUTED ISOQUIONLINE DERIVATIVES AS IMMUNOMUDULATORS

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases. (I)

TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS

A compound of formula (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from the group consisiting of H, halo, C1-4 alkoxy, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH-C1-4 alkyl and cyano; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2e is H or Me; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl; wherein when R2e is H, at least one of R1a, R1b, R1c and R1d is selected from C1-4 alkoxy, C2-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH-C1-4 alkyl and cyano.

Discovery of potent heterodimeric antagonists of inhibitor of apoptosis proteins (IAPs) with sustained antitumor activity

The prominent role of IAPs in controlling cell death and their overexpression in a variety of cancers has prompted the development of IAP antagonists as potential antitumor therapies. We describe the identification of a series of heterodimeric antagonists with highly potent antiproliferative activities in cIAP- and XIAP-dependent cell lines. Compounds 15 and 17 further demonstrate curative efficacy in human melanoma and lung cancer xenograft models and are promising candidates for advanced studies.

IAP ANTAGONISTS

There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.